Trial Profile

A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DS-9606a (Primary)
Indications Advanced breast cancer; Endometrial cancer; Gastric cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Giant cell tumours; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Daiichi Sankyo Inc

15 Sep 2024 According to Daiichi Sankyo media release , data from the study were presented at the 2024 European Society for Medical Oncology
15 Sep 2024 Results presented in the Daiichi Sankyo Media Release.
04 Sep 2024 According to Daiichi Sankyo media release , At ESMO, a proffered paper session will highlight preliminary results from this trial from Daiichi Sankyos Second ADC Platform and DXd ADC Data in Multiple Additional Cancers at ESMO

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com